Shafiq Muhammad, Rahman Hazir, Qasim Muhammad, Ayub Najma, Hussain Shagufta, Khan Jafar, Naeem Madiha
Eur J Microbiol Immunol (Bp). 2013 Dec;3(4):267-71. doi: 10.1556/EuJMI.3.2013.4.5. Epub 2013 Nov 21.
Enterobacteriaceae produces AmpC β-lactamases that make them resistant to commonly used antibiotics. AmpC β-lactamases can be chromosomal-mediated or plasmid-mediated AmpC β-lactamases (PABLs). The present study was undertaken to determine the occurrence of PABLs production in clinical isolates in Escherichia coli and Klebsiella pneumoniae. Among 1328 culture positive samples, 511 isolates were identified as E. coli (81.02%, n = 414) and K. pneumonia (18.98%, n = 97). Cefoxitin resistance was observed in E. coli (19.57%, n = 81) and K. pneumoniae (22.68%, n = 22). Out of these cefoxitin resistant isolates, 40.74% (n = 33) E. coli and 54.55% (n = 12) K. pneumoniae came out to be PABL producers. Prevalence of both PABLs and ESBLs in E. coli and K. pneumoniae was 29.24% (n = 8) and 47% (n = 5), respectively. Isolates coproducing PABLs and ESBL exhibited increased minimum inhibitory concentrations (MICs) for selected cephalosporins. This study documented a high frequency of PABLs producing isolates from hospital which may lead to serious therapeutic problem.
肠杆菌科细菌产生的AmpC β-内酰胺酶使其对常用抗生素具有耐药性。AmpC β-内酰胺酶可由染色体介导或质粒介导的AmpC β-内酰胺酶(PABLs)。本研究旨在确定大肠杆菌和肺炎克雷伯菌临床分离株中PABLs的产生情况。在1328份培养阳性样本中,511株分离菌被鉴定为大肠杆菌(81.02%,n = 414)和肺炎克雷伯菌(18.98%,n = 97)。在大肠杆菌(19.57%,n = 81)和肺炎克雷伯菌(22.68%,n = 22)中观察到头孢西丁耐药。在这些头孢西丁耐药分离株中,40.74%(n = 33)的大肠杆菌和54.55%(n = 12)的肺炎克雷伯菌为PABL产生菌。大肠杆菌和肺炎克雷伯菌中PABLs和ESBLs的患病率分别为29.24%(n = 8)和47%(n = 5)。同时产生PABLs和ESBLs的分离株对选定头孢菌素的最低抑菌浓度(MIC)升高。本研究记录了医院中产生PABLs的分离株的高频率,这可能导致严重的治疗问题。